Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
77 hedge funds and large institutions have $276M invested in Adamas Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 29 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
10% more funds holding
Funds holding: 70 → 77 (+7)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1% less capital invested
Capital invested by funds: $278M → $276M (-$2.5M)
5% less call options, than puts
Call options by funds: $453K | Put options by funds: $478K
28% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$4.86M |
| 2 |
BWCA
Brenner West Capital Advisors
New York
|
+$3.78M |
| 3 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$3.53M |
| 4 |
AI
Axiom Investors
Greenwich,
Connecticut
|
+$1.67M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.37M |
| 2 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
-$4.96M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$2.62M |
| 4 |
JP Morgan Chase
New York
|
-$2.53M |
| 5 |
BlackRock
New York
|
-$1.84M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MAM
76
Meeder Asset Management
Dublin,
Ohio
| $2K | -$2.46K | -149 | -62% |
|
77
Citigroup
New York
| $2K | +$1.6K | +97 | +9,700% |
|
|
TI
78
Trexquant Investment
Stamford,
Connecticut
| – | -$287K | -16,372 | Closed |
|
|
GWM
79
Geneos Wealth Management
Englewood,
Colorado
| – | -$5K | -290 | Closed |
|
|
LTFS
80
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$2K | -100 | Closed |
|
ADMS Hedge Fund Activity: Q2 2017 in Review
77 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q2 2017, worth a combined $276M — down 0.9% from $278M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ADMS positions and 3 closed out — a net gain of 7 holders — while 21 added to existing stakes and 29 trimmed.
The largest buyer was Armistice Capital, adding an estimated $4.86M. The largest seller was Great Point Partners, cutting an estimated $6.37M.
- 77 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q2 2017, up from 70 in Q1 2017.
- Funds reported $276M of Adamas Pharmaceuticals stock for Q2 2017, down 0.9% quarter-over-quarter.
- 10 funds opened new Adamas Pharmaceuticals positions in Q2 2017 and 3 closed out, a net change of +7 holders.
- The largest Adamas Pharmaceuticals buyer in Q2 2017 was Armistice Capital, an estimated $4.86M added.
- The largest Adamas Pharmaceuticals seller in Q2 2017 was Great Point Partners, an estimated $6.37M sold.
Based on aggregated 13F filings for Q2 2017.